See more : Japan Post Holdings Co., Ltd. (JPPHY) Income Statement Analysis – Financial Results
Complete financial analysis of DelMar Pharmaceuticals, Inc. (DMPWW) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of DelMar Pharmaceuticals, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
- Dechra Pharmaceuticals PLC (DPH.L) Income Statement Analysis – Financial Results
- Hawaiian Electric Company, Inc. PFD SER D 5% (HAWEM) Income Statement Analysis – Financial Results
- Videlio SA (VDLO.PA) Income Statement Analysis – Financial Results
- Jones Soda Co. (JSDA.CN) Income Statement Analysis – Financial Results
- Madras Fertilizers Limited (MADRASFERT.NS) Income Statement Analysis – Financial Results
DelMar Pharmaceuticals, Inc. (DMPWW)
Industry: Biotechnology
Sector: Healthcare
About DelMar Pharmaceuticals, Inc.
Kintara Therapeutics, Inc., a clinical stage drug development company, focuses on developing and commercializing anti-cancer therapies to treat cancer patients. It is developing two late-stage, Phase III-ready therapeutics, including VAL-083, a DNA-targeting agent for the treatment of drug-resistant solid tumors, such as glioblastoma multiforme, as well as other solid tumors, including ovarian cancer, non-small cell lung cancer, and diffuse intrinsic pontine glioma; and REM-001, a late stage photodynamic therapy for the treatment of cutaneous metastatic breast cancer, basal cell carcinoma nevus syndrome, and access graft failure in hemodialysis patients. Kintara Therapeutics, Inc. has a strategic collaboration with Guangxi Wuzhou Pharmaceutical (Group) Co. Ltd. to manufacture and sell VAL-083 in China. The company was formerly known as DelMar Pharmaceuticals, Inc. and changed its name to Kintara Therapeutics, Inc. in August 2020. Kintara Therapeutics, Inc. was incorporated in 2009 and is headquartered in San Diego, California.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | 55.00K | 60.00K | 60.00K | 32.00K | 10.00K | 16.35K | 24.53K | 16.68K | 10.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -55.00K | -60.00K | -60.00K | -32.00K | -10.00K | -16.35K | -24.53K | -16.68K | -10.29K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | 2.66M | 9.31M | 15.17M | 11.82M | 3.63M | 3.66M | 7.13M | 5.00M | 3.36M | 2.56M | 2,342.65B | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 5.79M | 5.49M | 7.51M | 9.76M | 4.51M | 4.74M | 4.04M | 3.32M | 2.85M | 2.17M | 3,952.31B | 0.00 | 0.00 | 33.14K | 5.58K |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 5.79M | 5.49M | 7.51M | 9.76M | 4.51M | 4.74M | 4.04M | 3.32M | 2.85M | 2.17M | 3,952.31B | 0.00 | 18.89K | 33.14K | 5.58K |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 8.45M | 14.80M | 22.68M | 21.57M | 8.14M | 8.40M | 11.17M | 8.32M | 6.21M | 4.72M | 6,294.96B | 0.00 | 18.89K | 33.14K | 5.58K |
| Cost & Expenses | 8.45M | 14.80M | 22.68M | 21.57M | 8.14M | 8.40M | 11.17M | 8.32M | 6.21M | 4.72M | 6,294.96B | 0.00 | 18.89K | 33.14K | 5.58K |
| Interest Income | 0.00 | 137.00K | 14.00K | 120.00 | 75.25K | 60.70K | 33.24K | 457.00 | 108.00 | 363.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 14.00K | 26.00K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 2.09K | 6.06K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 55.00K | 60.00K | 60.00K | 32.00K | 10.00K | 16.35K | 24.53K | 16.68K | 10.29K | 363.00 | 5.25K | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -8.40M | -14.74M | -22.62M | -38.15M | -9.12M | -8.03M | -11.11M | -8.07M | -8.85M | -4.72M | -8.28M | 0.00 | -18.89K | -33.14K | -5.58K |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -8.50M | -14.81M | -22.69M | -21.67M | -7.09M | -8.69M | -11.18M | -8.56M | -3.56M | -4.72M | 8,290.69B | 0.00 | -18.89K | -33.14K | -5.58K |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | 131.00K | 147.00K | 21.00K | -16.63M | -982.00K | 350.28K | 36.35K | 324.16K | -2.27M | 376.89K | -8.02K | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax | -8.50M | -14.65M | -22.66M | -38.30M | -9.13M | -8.05M | -11.14M | -8.08M | -8.86M | -4.80M | 8,290.69B | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 76.00K | -147.00K | -42.00K | 26.00K | 981.37K | -639.85K | -39.46K | -477.67K | 5.30M | 69.29K | 6.36K | 0.00 | 18.89K | 33.14K | 5.58K |
| Net Income | -8.50M | -14.65M | -22.62M | -38.32M | -10.11M | -7.41M | -11.14M | -8.08M | -8.86M | -4.80M | 8,290.69B | 0.00 | -18.89K | -33.14K | -5.58K |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -3.23 | -9.04 | -23.22 | -74.02 | -48.39 | -143.87 | -266.96 | -335.43 | -404.86 | -251.98 | 484.47M | 0.00 | -3.55 | -3.29 | -1.32 |
| EPS Diluted | -3.23 | -8.62 | -23.22 | -74.02 | -48.39 | -143.87 | -266.96 | -335.43 | -404.86 | -251.98 | 475.63M | 0.00 | -1.78 | -3.29 | -1.32 |
| Weighted Avg Shares Out | 2.64M | 1.62M | 974.00K | 517.72K | 208.88K | 51.49K | 41.72K | 24.09K | 21.90K | 19.03K | 17.11K | 9.42K | 5.31K | 10.08K | 4.22K |
| Weighted Avg Shares Out (Dil) | 2.64M | 1.70M | 974.00K | 517.72K | 208.88K | 51.49K | 41.72K | 24.09K | 21.90K | 19.03K | 17.43K | 11.12K | 10.60K | 10.08K | 4.22K |
Source: https://incomestatements.info
Category: Stock Reports